Business Description
![BerGenBio ASA BerGenBio ASA logo](https://static.gurufocus.com/logos/0C0000B8RH.png?14)
BerGenBio ASA
ISIN : NO0013251173
Compare
Compare
Traded in other countries / regions
BGBIO.Norway7BG0.Germany0RU5.UKBGBIOO.SwedenBRRGD.USA IPO Date
2017-04-07Description
BerGenBio ASA is a clinical-stage biopharmaceutical Company focused on developing novel medicines for aggressive diseases. The company's clinical asset, bemcentinib, targeting the receptor tyrosine kinase AXL, is currently in development in a Ph1b/2a study in 1L STK 11 mutated NSCLC and preclinical development for severe respiratory infections.
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 280.74 | |||||
Equity-to-Asset | 0.69 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 1.48 | |||||
WACC vs ROIC |
Growth Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -66.9 | |||||
3-Year EBITDA Growth Rate | 64.5 | |||||
3-Year EPS without NRI Growth Rate | 64.7 | |||||
3-Year FCF Growth Rate | 61.2 | |||||
3-Year Book Growth Rate | -80.7 |
Momentum Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 58.42 | |||||
9-Day RSI | 55.88 | |||||
14-Day RSI | 51.95 | |||||
6-1 Month Momentum % | -59.95 | |||||
12-1 Month Momentum % | 33.03 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 3.21 | |||||
Quick Ratio | 3.21 | |||||
Cash Ratio | 2.79 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -198.5 | |||||
Shareholder Yield % | -53.12 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -30549.14 | |||||
Net Margin % | -29658.54 | |||||
FCF Margin % | -35200 | |||||
ROE % | -131.32 | |||||
ROA % | -93.78 | |||||
ROIC % | -775.44 | |||||
ROC (Joel Greenblatt) % | -57579.03 | |||||
ROCE % | -132.35 |
GF Value Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 641.05 | |||||
PB Ratio | 3.51 | |||||
Price-to-Tangible-Book | 3.51 | |||||
EV-to-EBIT | -2.3 | |||||
EV-to-Forward-EBIT | -1.71 | |||||
EV-to-EBITDA | -2.31 | |||||
EV-to-Forward-EBITDA | -1.71 | |||||
EV-to-Revenue | 688.55 | |||||
EV-to-Forward-Revenue | 1793.67 | |||||
EV-to-FCF | -1.96 | |||||
Price-to-Net-Current-Asset-Value | 3.52 | |||||
Price-to-Net-Cash | 4.35 | |||||
Earnings Yield (Greenblatt) % | -43.48 | |||||
FCF Yield % | -38.52 |